Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
OptimizeRx Q1 2026 Earnings Call - Revenue Guidance Cut Amid MFN Headwinds, But AI and Programmatic DSP Integration Offer Long-Term Upside
OptimizeRx delivered a solid Q1 2026, beating consensus on the top and bottom line, but management cut full-year revenue guidance to $95M-$100M due to short-term disruptions from Most Favored Nation (...
- Revenue Guidance Cut: Full-year 2026 revenue guidance lowered to $95M-$100M due to MFN-related disruption and cautious pharma budgeting, though adjusted EBITDA guidance of $21M-$25M is maintained.
- Q1 Results Beat Consensus: Q1 revenue was $19.8M (-10% YoY) but adjusted EBITDA rose 120% to $3.3M, beating estimates. Non-GAAP net income doubled to $2.7M.
- MFN Headwinds Persist: Contracted revenue remains 15-20% behind prior year levels, primarily driven by shorter contract durations as pharma clients react to Most Favored Nation pricing dynamics.
- +9 more takeaways
Kura Oncology Q1 2026 Earnings Call - KOMZIFTI Launch Exceeds Expectations with 40% New Patient Share
Kura Oncology’s first full quarter as a commercial entity is off to a strong start. KOMZIFTI (ziftomenib) generated $5.8 million in net product revenue, driven by 85 new patient starts across 60 activ...
- KOMZIFTI generated $5.8 million in net product revenue in Q1 2026, surpassing management's initial expectations for the first full quarter of launch.
- The company secured 85 new patient starts across approximately 60 activated accounts, capturing roughly 40% of the new patient market share in the NPM1-mutant AML space despite being second-to-market.
- Physicians are actively switching patients from competing menin inhibitors to KOMZIFTI, signaling early product differentiation based on efficacy, safety, and dosing convenience.
- +7 more takeaways
MaxCyte Q1 2026 Earnings Call - Core Revenue Misses, but Restructuring and New Products Signal Turnaround
MaxCyte reported $9.7 million in Q1 2026 revenue, missing expectations as core revenue fell 25% year-over-year to $6.2 million due to inventory management at its largest customer and discontinued SPL ...
- Total revenue of $9.7 million missed expectations, driven by a 25% YoY decline in core revenue to $6.2 million due to inventory management at its largest customer and discontinued SPL programs.
- SPL program-related revenue rose 62% YoY to $3.4 million, including a $3 million regulatory milestone from a clinical customer dosing in a registrational study.
- Operating expenses fell $7 million YoY to $14.3 million, reflecting the full impact of 2025 restructuring and cost efficiency actions, with no meaningful OpEx growth expected going forward.
- +7 more takeaways
Nyxoah Q1 2026 Earnings Call - U.S. Revenue Acceleration and Reimbursement Clarity Drive Q2 Outlook
Nyxoah reported a strong start to 2026, with Q1 worldwide net revenue rising 13% sequentially to EUR 6.4 million, driven by a 25% surge in U.S. sales. The company achieved its first full quarter of U....
- Q1 2026 worldwide net revenue reached EUR 6.4 million, up 13% sequentially, with U.S. net revenue surging 25% to EUR 4.3 million.
- U.S. commercial execution is accelerating, with 40 active sales reps now covering 200 of the 400 targeted high-volume accounts.
- Surgeon adoption is deepening, with 207 total surgeons trained and 91 active accounts (surgeons trained and VAC committee approved) out of 125 targeted sites.
- +7 more takeaways
Verrica Pharmaceuticals First Quarter 2026 Earnings Call - YCANTH Sales Accelerate, Pipeline Advances
Verrica Pharmaceuticals reported accelerating demand for its molluscum treatment YCANTH in the first quarter of 2026, with U.S. revenue rising 25.4% year-over-year to $4.3 million and dispensed applic...
- U.S. YCANTH revenue rose 25.4% year-over-year to $4.3 million in Q1 2026, driven by a 51.3% increase in dispensed applicator units to 15,302.
- YCANTH achieved a new record for monthly dispensed applicator units in March 2026, with demand continuing to accelerate into April.
- Torii Pharmaceutical launched YCANTH in Japan for molluscum treatment in February 2026, following regulatory approval, marking a key international milestone.
- +7 more takeaways
Relmada Therapeutics Q1 2026 Earnings Call - Phase III RESCUE Program on Track with $160 Million War Chest and Compelling 12-Month Bladder Cancer Data
Relmada Therapeutics entered the second half of 2026 with a fortified balance sheet and clear regulatory pathways. The company secured $160 million in private financing, pushing its cash position to $...
- Relmada closed Q1 2026 with a cash balance of $234 million, following a $160 million private placement completed in March 2026. This fortifies the balance sheet and provides sufficient runway to fund operations and complete the Phase III RESCUE program through 2029.
- The company remains on track to initiate the Phase III RESCUE registrational program for NDV-01 in mid-2026, following successful FDA alignment on the trial design and endpoints.
- NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel, demonstrated a 76% complete response (CR) rate at 12 months in the overall Phase II population of high-risk non-muscle invasive bladder cancer (NMIBC).
- +9 more takeaways
Stereotaxis Q1 2026 Earnings Call - New Disposable Ecosystem Begins to Replace Legacy J&J Supply
Stereotaxis is navigating a painful but structurally transformative transition. The company is actively winding down its two-decade-old dependency on Johnson & Johnson catheters while rolling out an e...
- Revenue of $6.3 million in Q1 2026, down from $7.5 million year-ago, reflecting a transitional period as legacy J&J catheter supply winds down before the new disposable ecosystem scales.
- Management is actively replacing a 20-year dependency on Johnson & Johnson catheters with a new proprietary disposable business, expecting annual revenue to surpass $40 million with double-digit growth.
- Initial MAGiC catheter procedures are generating $5,000 to $8,000 in recurring revenue per case, a massive step-up from legacy hardware sales, with European hospitals already ordering $100,000 in disposables for a single month.
- +9 more takeaways
TriSalus Life Sciences Q1 2026 Earnings Call - Landmark Real-World Evidence Validates PEDD, Commercial Expansion Drives Revenue Transition
TriSalus Life Sciences reported a deliberate but costly transition in its first quarter, as a massive commercial expansion temporarily disrupted sales while laying the groundwork for future growth. Re...
- Revenue for Q1 2026 was $8.9 million, slightly down from $9.2 million in the prior year period, primarily due to transition costs associated with a major commercial expansion.
- Gross margin improved to 86% from 84% in the prior year, driven by lower average unit costs on TriNav and continuous manufacturing improvements.
- The company is executing a deliberate commercial realignment, doubling its sales force and expanding its territory footprint to capture growth across a $2.5 billion addressable market.
- +11 more takeaways
GrowGeneration Q1 2026 Earnings Call - Commercial B2B Momentum and Proprietary Brand Expansion Drive Revenue Growth
GrowGeneration delivered its second consecutive quarter of year-over-year revenue growth in Q1 2026, with net sales rising 7.5% to $38.4 million. The company’s strategic pivot toward a commercially dr...
- GrowGeneration reported Q1 2026 net sales of $38.4 million, up 7.5% year-over-year, marking its second consecutive quarter of revenue growth.
- Proprietary brand sales now represent 37% of cultivation and gardening revenue, up from 32% in the prior year, reflecting a strategic shift toward higher-margin, recurring consumable products.
- The storage solutions segment drove significant growth, with net sales increasing 35.5% year-over-year to $6.5 million, benefiting from increased capital investment across broader end markets.
- +7 more takeaways
a.k.a. Brands Q1 2026 Earnings Call - Gross Margin Expansion Signals Structural Turnaround
a.k.a. Brands delivered a resilient first quarter, with net sales rising 3% to $132.5 million and Adjusted EBITDA jumping to $5.1 million, well above prior expectations. The headline story is the 180 ...
- Net sales grew 3% year-over-year to $132.5 million, slightly ahead of company guidance, driven by 3.2% U.S. sales growth and 3.8% Australian sales growth.
- Adjusted EBITDA more than doubled to $5.1 million from $2.7 million, with the margin expanding 180 basis points to 3.9%.
- Underlying gross margin expanded 180 basis points to 59%, fueled by inventory discipline, stronger full-price sell-through, and the rollout of the test-and-repeat model, primarily in the streetwear division.
- +7 more takeaways